Last reviewed · How we verify
Atropine 0.05% eyedrops
At a glance
| Generic name | Atropine 0.05% eyedrops |
|---|---|
| Also known as | Low-concentration atropine |
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control (PHASE3)
- Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY) (PHASE3)
- Changes in Eye Shape With Myopia Management Interventions (PHASE4)
- Myopia Progression Control Using Atropine 0.05% After Pediatric Cataract Surgery And Intraocular Lens Implantation Surgery (NA)
- Myopia Control in Children: Comparison of Defocus Incorporated Multiple Segments® Lenses Versus Atropine 0.05% Eyedrops (NA)
- Early-Onset Myopia Intervention Project (NA)
- Efficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center (PHASE2, PHASE3)
- MAD Trial: Myopia Atropine Dose (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atropine 0.05% eyedrops CI brief — competitive landscape report
- Atropine 0.05% eyedrops updates RSS · CI watch RSS
- Fondation Ophtalmologique Adolphe de Rothschild portfolio CI